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glyco-phosphoprotein, plays an important role in
autoimmune-mediated demyelinating diseases, including
multiple sclerosis and experimental autoimmune
encephalomyelitis (EAE). As an integrin and CD44 binding
protein it participates in bidirectional communication
between the ECM and target cells and aﬀects transduction
pathways thatmaintain neuronal and immune cell homeosta-
sis. Its biological activity is also heavily inﬂuenced by
microenvironment, which stimulates the cleavage of OPN
and changes its functions. In this study we estimated the
expression proﬁle of OPN in neural tissues of DA rats during
the ﬁrst relapse of chronic relapsing EAE and investigated
the relationship of OPN tometallothionein I + II (MTs), which
play pivotal role in zinc-related cell homeostasis and in pro-
tection of CNS against cytokine-induced injury. The data
showed that in EAE rats OPN mRNA and protein levels
increased concurrently with the transcription of MTs and that
within the spinal cord (SC) lysates EAE-aﬄicted rats had a
higher content of OPN fragments of low molecular weight
than untreated and CFA-treated rats. The expression of
OPN and MTs was upregulated on ependymal, lymphoid
and astroglial cells and on multiple avb3+ neurons in SC
and in the brain (cortex, white matter, hippocampus, and
cerebellum). Besides, multiple cells co-expressed OPN and
MTs. Granular OPN signals were detected in secretory vesi-
cles of Golgy (avb3 neurons) and in patches adjacent to the
plasma membrane (subventricular zone). The ﬁndings
imply that in demyelinating lesions are generated proteolytic
OPN fragments and that OPN/MT interactions contribute to
tissue remodeling during an autoimmune attack.  2017
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133INTRODUCTION
Osteopontin (OPN), known also as secreted
phosphoprotein 1 and early T lymphocyte activation 1
(ETA-1) is an extracellular matrix (ECM) protein, which
belongs to a family of small integrin-binding ligand N-
linked glycoproteins (SIBLINGs). It was ﬁrst described
by Senger and coauthors as a 60-kDa phosphoprotein,
secreted from transformed mammalian cells (Senger
et al., 1979). Lately, it was identiﬁed in osteoblasts and
bone calciﬁed matrix, but today it is known that OPN acts
as a pleiotropic cytokine, which in various cells aﬀects
multiple physiological and pathological processes
(Ashkar et al., 2000; Fisher et al., 2001; Bellachene,
2008).
Current knowledge also shows that functional
properties of SIBLINGs depend on functions of
extracellular proteases and cellular uptake of ECM
proteins or their proteolysed fragments, as well as on
processes that regulate their traﬃcking into the
secretory and the endo/lysosomal degradation pathways
inside the cells (Bellachene, 2008; Hellewell and
Adams, 2015). Importantly, some ECM components after
proteolysis may exhibit diﬀerential biological activities
owing to the removal of functional domains or exposure
of cryptic binding sites (Fedarko et al., 2004).
In this context it is known that full length OPN contains
an arginine-glycine-aspartate (RGD) motif at NH2-
terminal fragment and a protease-hypersensitive
cleavage site that separates the integrin-binding site
from the C-terminal fragments of OPN containing CD44
binding domains (reviewed by (Okamoto, 2007; Scatena
et al., 2007). The RGD sequence, which is 100% con-
served between species, acts as a major binding site for
av/b3, av/b1, a5/b1, a8/b1, and av/b5 integrins (Ashkar
et al., 2000; Denhardt et al., 2001). Cleavage by thrombin
at Arg168–Ser169 exposes a serine-valine valine-tyro
sine-glutamate-leucine-arginine (SVVYGLR) domain
(human) or SLAYGLR domain (mouse and rat). It is cryp-
tic in intact OPN, but after cleavage with thrombin it binds
a9/b1 and a4/b1 integrins that are the main adhesion
molecules involved in lymphocyte transmigration to the
brain (Smith et al., 1996; Yokosaki et al., 1999; Green
et al., 2001; Boggio et al., 2016). Importantly, additional
cleavage of OPN within the SVVYGLR site may be
induced by several MMPs, including MMP2, MMP3,
MMP7, MMP9, and MMP12 (Agnihotri et al., 2001; Gaoons.org/licenses/by-nc-nd/4.0/).
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2010). These new MMP-cleaved OPN fragments may
exhibit reduced ability to bind a4/a9 integrins (Yokosaki
et al., 2005), but also the greater adhesive and migratory
activities than full-length OPN (Gao et al., 2004).
Through sequences in C-terminal fragment OPN
interacts also with CD44v3–v6 splice variants in an
RGD independent manner (Weber et al., 1999) and par-
ticipates in immune regulation (Guan et al., 2011) and in
tumorigenesis (Teramoto et al., 2004). Besides, OPN
molecule contains heparin binding, hydroxyapatitite and
calcium binding regions and domains responsible for
transglutamination, as well as multiple Ser and Thr phos-
phorylation sites and sites for N- and O-linked glycosyla-
tion (Okamoto, 2007; Scatena et al., 2007).
Furthermore, along to its classically secreted form (s-
OPN) OPN also exists in an intracellular form (i-OPN)
(Shinohara et al., 2008a; Cantor and Shinohara, 2009;
Hellewell and Adams, 2015; Rittling and Singh, 2015). It
may be generated from the same mRNA as s-OPN by
alternative translation of a non-AUG site downstream of
the canonical AUG sequence and accompanied by dele-
tion of the N-terminal 16-aa signal sequence that targets
nascent protein to secretory vesicles (Shinohara et al.,
2008b). Reports show that this form of OPN is a critical
regulator for Toll like receptor-9 (TLR-9), TLR-7-
dependent interferon-alpha (IFN-alpha) expression by
plasmacytoid dendritic cells (DCs) and TH17 develop-
ment (Shinohara et al., 2008a; Cantor and Shinohara,
2009; Morimoto et al., 2010; Inoue and Shinohara,
2011; Hellewell and Adams, 2015).
Collectively, these data emphasize that pleiotropic
functions of OPN depend on discrete changes in
domains, on generation of its active cleaved products
and on processes of posttranslational modiﬁcations,
such as phosphorylation, glycosylation and sulphation
that may generate diﬀerent functional forms of OPN.
As a multi-faceted molecule OPN plays an important
role also in neurodegenerative diseases, such as
Parkinson’s and Alzheimer’s disease, as well as in
multiple sclerosis (MS) and its animal model
experimental autoimmune encephalomyelitis (EAE)
(Steinman, 2009; Braitch and Constantinescu, 2010;
Carecchio and Comi, 2011; Niino and Kikuchi, 2011). In
these conditions OPN is mainly considered an inﬂamma-
tory molecule, but since in some contexts OPN may func-
tion as a neuroprotectant, its ambiguous and ‘‘double-
edged” sword activities have been often emphasized
(Carecchio and Comi, 2011).
The detrimental role of OPN in MS and EAE was ﬁrst
reported by Chabas and colleagues (2001) who showed
that OPN transcript was abundant in plaques dissected
from brains of patients with MS and within SC tissue of
rats paralyzed by EAE, as well as that OPN/ mice
were resistant to progressive EAE. They also found that
myelin-reactive T cells in OPN/ mice produced more
interleukin-10 (IL-10) and less interferon-c than in OPN
+/+ mice, proposing that OPN might regulate T helper
cell-1 (TH1)-mediated autoimmune diseases (Chabas
et al., 2001). The data were conﬁrmed by ﬁndings that
OPN-deﬁcient mice had attenuated EAE and decreasedinﬂammatory inﬁltration and demyelination in the spinal
cords (Jansson et al., 2002), by data showing that treat-
ment of EAE mice with recombinant (r) OPN might exac-
erbate the disease in OPN-deﬁcient mice and trigger
neurological relapse by inhibiting apoptosis of autoreac-
tive immune cells (Hur et al., 2007), as well as by ﬁndings
that anti-OPN treatment might reduce clinical severity of
EAE and IL-17 production (Murugaiyan et al., 2008).
It should be also emphasized that the expression
proﬁle of OPN and its receptors show, time- and cell-
dependent patterns (Kang et al., 2008), as well as that
OPN functions strictly depend on microenvironment in
which thrombin (Boggio et al., 2016), or diﬀerent MMPs
(Agnihotri et al., 2001; Gao et al., 2004; Hou et al.,
2004; Goncalves DaSilva et al., 2010) contribute to prote-
olytic cleavage of OPN and generation of OPN fragments
with distinct functions.
In this context, it has been shown that the RGD-
binding domain of OPN might also enhance the survival
of tyrosine hydroxylase (TH)-positive cells in rat
substantia nigra against toxic insults (Iczkiewicz et al.,
2010), as well as that OPN in distinct conditions might
have not only detrimental, but also a protective properties
(Braitch and Constantinescu, 2010; Carecchio and Comi,
2011; Brown, 2012), participating in processes of remyeli-
nation (Zhao et al., 2008), in regeneration of peripheral
motor axons (Wright et al., 2014), hippocampal neurons
(Plantman, 2012) and nigral cells (Iczkiewicz et al., 2006).
In the present study, we examined the possibility that
in the remodeling processes that take part in EAE OPN
co-operates with metallothioneins (MTs), since this
family of phylogenetically highly conserved proteins
generally provide cytoprotective action against oxidative
injury, DNA damage and apoptosis (Miles et al., 2000;
Coyle et al., 2002). As metal-binding and cysteine-rich
proteins they participate in maintenance of Zn and Cu
homeostasis, in protection against cytotoxicity of toxic
metals, as well as in regulation of basic cellular pro-
cesses, such as gene expression, apoptosis, proliferation,
and diﬀerentiation. Furthermore, acting through thiol
groups, MTs ensure the protection against various types
of injuries resulting from reactive oxygen (ROS) or nitro-
gen species (RNS), providing anti-inﬂammatory and
immunoregulatory functions (Andrews, 2000;
Mocchegiani et al., 2000; Rink and Haase, 2007; Inoue
et al., 2009; Isani and Carpene, 2014; Ling et al., 2016).
Importantly, it is generally accepted that MT isoforms
MT-I + II, have marked neuroprotective capacities
(Penkowa, 2006; Pedersen et al., 2009; Manso et al.,
2011), and an impressive regulatory eﬀect in demyelinat-
ing and inﬂammatory disease, such as MS and EAE
(Penkowa et al., 2003; Penkowa and Hidalgo, 2003).EXPERIMENTAL PROCEDURES
Experimental animals
Experiments were performed on male Dark Agouti (DA)
rats, aged 2–3 months. They were housed under
standard conditions of light, temperature and humidity
with unlimited access to food and water. Experimental
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and rules (NN 135/06; NN 37/13; NN 125/13; NN
055/2013) and with the guidelines set by European
Community Council Directive (86/609/EEC).
Experimental protocol was approved by the Ethics
Committee of the University of Rijeka.EAE induction and evaluation
Induction of chronic relapsing (CR)-EAE was performed
in male DA rats by bovine brain white matter
homogenate emulsion (BBH) in the complete Freund’s
adjuvant (CFA) (Sigma, St. Louis, Mo., USA), as
previously described (Jakovac et al., 2011). To each ani-
mal 2  0.1 mL emulsion was injected subcutaneously in
each hind footpad. Control group was injected with the
same dose of CFA. The evaluation of the clinical course
was assessed daily using the following criteria: 0 – no
symptoms; 1 – ﬂaccid paralysis of tail; 2 – hind legs pare-
sis; 3 – hind legs paralysis with incontinence and 4 –
death of the animal.Tissue preparation for paraﬃn slices
Animals with clinical score 3 (hind legs paralysis with
incontinence) were sacriﬁced by exsanguination on day
13 or 14 after immunization. The exsanguination was
done in deep anesthesia, induced by combination of
Ketamine (80 mg/kg) and Xylasine (5 mg/kg), given by
intraperitoneal (i.p.) injection, according to the guidance
of European Community Council Directive (86/609/EEC)
and recommendation of National Centre for the
Replacement, Reﬁnement and Reduction of Animals in
Research (www.nc3rs.org.uk). The tissue samples of
the lumbar spinal cord and the brain were rapidly
removed from nine rats and ﬁxed in 4% buﬀered
paraformaldehyde (Sigma, Aldrich, St. Lois, MD, USA)
solution during 24 h. Tissue was then embedded in
paraﬃn wax and sections were cut at 4 lm using HM
340E microtome (Microtom, Germany). Heat induced
epitope retrieval was done prior to staining procedure by
heating tissue slides in boiled citrate buﬀer pH 6.0 four
times, each 5 min, using a microwave steamer.Immunohistochemistry
Immunohistochemical labeling of MT I + II proteins was
performed on paraﬃn embedded tissues using DAKO
EnVision + System, Peroxidase (DAB) kit according to
the manufacturer’s instructions (DAKO Cytomation,
Glostrup, Danmark), as previously described (Jakovac
et al., 2011). Brieﬂy, after washing and blocking non-
speciﬁc binding and endogenous peroxidase activity
mouse monoclonal anti-MT I + II IgG1 antibody (clone
E9; Dako Cytomation, Glostrup, Denmark; 1:50 with 1%
BSA in PBS) were added to tissue samples and incubated
overnight at 4 C in a humid environment, followed by
45 min incubation with peroxidase labeled polymer conju-
gated to goat anti-mouse immunoglobulins containing
carrier protein linked to Fc fragments to prevent nonspeci-
ﬁc binding. The immunoreaction product was visualized
by adding substrate-chromogen (DAB) solution.For immunohistochemical analysis of OPN expression
deparaﬃnized tissue sections were incubated with 1%
BSA in PBS for one hour at room temperature to block
non-speciﬁc binding. Immediately afterward, incubation
with goat polyclonal anti-OPN IgG antibody, which
recognizes all OPN isoforms (R&D, Minneapolis, MN,
USA, 1:200 with 1% BSA in PBS) was performed
overnight at 4 C in a humid environment. After
washing, tissues were incubated with secondary HRP
horse anti-goat IgG antibodies (Vector Laboratories,
Burlingame, CA, USA, 1:400 with 1% BSA in PBS) for
one hour at room temperature in a humid environment.
Immunoreactivity was visualized using DAB solution.
All tissues were counterstained with hematoxylin,
dehydrated through gradient of ethanol, mounted using
Entelan (Sigma-Aldrich, St. Lois, MO, USA) and
examined with Olympus BX51 microscope (Olympus,
Tokyo, Japan). The speciﬁcity of staining was conﬁrmed
by negative controls. For OPN-immunostaining, tissue
samples were treated with an identical procedure under
the same conditions, but with the omission of polyclonal
primary antibodies. For MT-I + II-immunostaining,
tissue samples were incubated with isotype-matched
irrelevant antibodies (mouse IgG1 immunoglobulin,
clone DAK-G01; Dako Cytomation, Glostrup, Danmark).
Immunoﬂuorescence
Immunoﬂuorescence labeling was also performed on
paraﬃn-embedded tissue sections. Nonspeciﬁc binding
was blocked by one-hour incubation with 1% BSA in
PBS containing 0.001% NaN3 at room temperature. The
following primary antibodies were used: goat anti-OPN
IgG (R&D, Minneapolis, MN, USA, 1:200), rabbit anti-
Integrin beta 3 IgG (Abcam, Cambridge, UK, 1:100), rat
anti-CD44 as a supernatant from rat hybridoma, clone
IM7 (own production), mouse anti-MT-I + II IgG1 (clone
E9; Dako Cytomation, Glostrup, Denmark; 1:50), rabbit
anti-GFAP IgG (Abcam, Cambridge, UK, 1:5000), rabbit
anti-NeuN IgG (Abcam, Cambridge, UK, 1:100), mouse
anti-GM130 IgG1 (clone 35, BD Bioscience, San Jose,
CA, SAD, 1:100) and mouse anti-proliferating cellular
nuclear antigen (PCNA) IgG2a (Abcam, Cambridge, UK,
1:100). Primary antibodies were diluted in blocking
solution and incubated with tissue sections overnight at
4 C in a humid environment. To visualize
immunocomplexes, the following secondary antibodies
were used: Alexa Fluor donkey anti-rabbit IgG 594 nm
(Molecular Probes, Carlsbad, CA, USA, 1:500), Alexa
Fluor donkey anti-goat IgG 488 nm (Molecular Probes,
Carlsbad, CA, USA, 1:300), Alexa Fluor donkey anti-rat
IgG 594 nm (Molecular Probes, Carlsbad, CA, USA,
1:500), Alexa Fluor goat anti-mouse IgG1 555 nm
(Molecular Probes, Carlsbad, CA, USA, 1:500) and
Alexa Fluor goat anti-mouse IgG 488 nm Molecular
Probes, Carlsbad, CA, USA, 1:300). Secondary
antibodies were diluted in blocking solution and
incubated with tissue sections in the dark for 1 h at
room temperature in a humid environment. Nuclei were
visualized with 40,6-diamidino-2-phenylindole,
dihydrochloride (DAPI, Molecular Probes, Carlsbad, CA,
USA). The speciﬁcity of the reaction was conﬁrmed by
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identical procedure under the same conditions.
Images were captured on Olympus imaging system
BX51 equipped with DP71CCD camera (Olympus,
Tokyo, Japan) and CellF imaging software was used.Western blot analyses
Spinal cords were collected from rats treated with BBH
+ CFA (N= 3), with CFA (N= 3) and from untreated
(N= 3) rats. Samples were snap-frozen in liquid
nitrogen for protein isolation and stored at 80 C.
Tissue was transferred in hypotonic buﬀer consisting of
10 mM HEPES (pH 7.9), 1.5 mM magnesium chloride,
10 mM potassium chloride, 10 mM 2-mercaptoethanol
and protease inhibitor cocktail (Complete, Mini, EDTA-
free tablets, Sigma Aldrich, St. Lois, MO, USA,
Germany) as well as 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF; Serva, Germany) and homogenized three times
for 15 s with tissue homogenizer (Biospec, Bartlesville,
OK, USA). The samples were left on ice for 15 min
before adding Nonidet P40 (Sigma Aldrich, St. Lois,
MO, USA) to a ﬁnal concentration of 0.5% and then
centrifuged at 3000 rpm for 1 min at 4 C. The resulting
supernatants were centrifuged at 14,000 rpm for 30 s at
4 C. Obtained supernatants with cytoplasmic proteins
were used for further procedure (Huber et al., 2007).
Proteins were separated by 10% (OPN) and 13,5%
(MT-I + II) sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE), under reducing (OPN)
and non-reducing (MT-I + II) conditions and then
transferred onto a nitrocellulose membrane (BioRad,
Hercules, CA, USA). Membranes were blocked with 5%
BSA (Sigma, Aldrich, St. Lois, MO, USA) in tris-buﬀered
saline with 0.05% Tween-20 (TBST) and incubated with
goat anti-OPN IgG antibody (R&D systems,
Minneapolis, MN, USA; 1:500) and mouse anti-MT-I + II
IgG1 antibody (clone E9; Dako Cytomation, Glostrup,
Danmark; 1:200), followed by incubation with species
speciﬁc HRP-conjugated secondary antibodies. The
rabbit anti-b-tubulin (Abcam, Cambridge, UK, 1:25,000)
was used as a control of cytoplasmic proteins. The
mouse anti-b-actin (Millipore, Darmstadt, Germany,
1:80,000) was used as a control of protein loading. For
detection membranes were, incubated with Amersham
ECL Prime (GE Healthcare, Sweden), and scanned with
Kodak Image Station 440CF (Kodak, USA). The
intensity of the bands was quantiﬁed using ImageJ
software (http://rsb.info.nih.gov/ij/). To determine the
relative expression of analyzed proteins in spinal cord of
immunized animals and animals treated only with CFA,
the band density of each sample was compared with the
band intensity obtained from spinal cord of untreated
animals after normalization to an internal control b-actin.RNA extraction, reverse transcription and real-time
PCR analysis
Spinal cords were collected from rats treated with BBH
+ CFA (N= 4), with CFA (N= 4) and from untreated
(N= 4) rats. Samples were snap-frozen in liquid
nitrogen for RNA isolation and stored at 80 C. TotalRNA was extracted from frozen tissues, using Trizol
Reagent (Invitrogen, Carlsbad, CA, USA), according to
the protocol provided by the manufacturer (1 ml of Trizol
per 100 mg of tissue). RNA was assayed by ultraviolet
spectrophotometric measurements at a wavelength of
260 nm, and its purity was estimated by the ratio of
A260/A280. Total RNA (5 lg) was treated with turbo
DNA-free reagent (Ambion; Applied Biosystems,
Carlsbad, CA, USA) to remove possible contamination
with genomic DNA, followed by reverse transcription
(High Capacity cDNA Reverse Transcription Kit; Applied
Biosystems, Carlsbad, CA, USA), according to the
manufacturer’s instructions. Relative expression levels
of OPN and MT-1 mRNA were determined by real-time
PCR analysis using SYBR Green PCR Universal
Mastermix (Applied Biosystems, Carlsbad, CA, USA)
according to the manufacturer’s instructions.
Oligonucleotide primers for rat OPN (forward 50-ACAG
TATCCCGATGCCACAG-30; reverse 50-GACT
CATGGCTGGTCTTCCC-30), rat MT-1 (forward 50-CAC
CGTTGCTCCAGATTCAC-30; reverse 50-GCAGCAG
CACTGTTCGTCAC-30) previously published (Banni
et al., 2010) and rat b-actin (forward 50-CCAC
CAGTTCGCCATGGAT-30; reverse 50-CCATACCCAC
CATCACACCC-30) were obtained from Metabion (Pla-
negg, Germany). ABI Prism 7300 Sequence Detector
System (Applied Biosystems, Carlsbad, CA, USA) was
used to perform quantitative PCR. Relative mRNA levels
were determined after normalization to b-actin.Statistical analysis
The statistical analyses were performed using Statistica
software version 12 (StatSoft Inc., Tulsa, OK, USA).
The distribution of data was tested for normality using
the Kolmogorov–Smirnov test. Diﬀerences between
groups were assessed with either one-way analysis of
variance (ANOVA) followed by the post hoc Scheﬀe´ test
or by Kruskal–Wallis and Mann–Whitney U test.
Statistical diﬀerences with p< 0.05 were considered
signiﬁcant.RESULTS
EAE was induced in genetically susceptible DA rats,
which react on immunization with BBH in CFA by
development of chronic-relapsing form of disease. It is
characterized by appearance of two peaks of clinical
symptoms, but since previously we found that MT-I
transcription and MT-I + II immunoreactivity in neural
tissues were signiﬁcantly upregulated particularly during
the ﬁrst attack of EAE that occurs on day 13 or 14 after
the immunization with BBH+ CFA (Jakovac et al.,
2011; Grubic-Kezele et al., 2013), in this study we sacri-
ﬁced the rats, exhibiting stage 3 of disease (hind legs
paralysis with incontinence) at the same time (Fig. 1).
Expression proﬁles of OPN and MT-I + II were examined
in spinal cord and in the brain and the data were com-
pared with ﬁndings in untreated rats and in CFA-treated
rats, sacriﬁced at the same post-immunization (p. i.)
day. As shown on Fig. 1, these control rats, in contrast
Fig. 1. Study design and clinical course of EAE in Dark Agouti (DA). Rats were immunized by
injection of bovine brain homogenate (BBH) in complete Freund’s adjuvant (CFA) or with CFA and
examined daily for clinical signs of EAE and scored as: 0 – no symptoms; 1 – ﬂaccid paralysis of
tail; 2 – hind legs paresis; 3 – hind legs paralysis with incontinence and 4 – death of the animal.
Pairs of BBH+ CFA and CFA-treated rats were sacriﬁced on the 13th or on the 14th post-
immunization (p.i.) day, i.e. at the time when rats immunized with encephalitogen exhibited hind
legs paralysis with incontinence (stage 3 of disease). Data are mean ± SE (N= 10/group).
***p< 0.001). (Mann–Whitney U test).
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any clinical symptom of disease (p< 0.001).Expression of OPN during the ﬁrst relapse of EAE in
spinal cord
Proﬁling of OPN mRNA and proteins by qPCR and
Western blot (WB) showed that transcription of OPN
gene was signiﬁcantly greater in rats immunized with
encephalitogen than in control rats (Fig. 2A; p< 0.05).
Moreover, WB revealed that in these rats the
cytoplasmic SC lysates contained more OPN fragments
of small molecular length (32 kDa) than intact and CFA-
treated rats (Fig. 2B, C; p< 0.05), implying that
immunization had stimulated the proteolytic cleavage of
OPN. Immunohistochemical data (Fig. 2D) also showed
that OPN expression in EAE rats was highly
upregulated around plaques (a) and on cells
surrounding blood vessels in white matter (b, e, red
head arrow), in choroid plexus and subarachnoid places
(c, d), as well as in numerous motor neurons in the gray
matter of spinal cord (f). The absence of these changes
in rats treated with CFA (Fig. 2D g, h) conﬁrmed that
they were speciﬁc for encephalitogen. Besides, all slides
used as negative controls, did not show any
immunopositivity (Fig. 2D, inserts on g, h).Expression of MT I + II during the ﬁrst relapse of EAE
in spinal cord
Simultaneously, in agreement with our previous results
(Jakovac et al., 2011; Grubic-Kezele et al., 2013) we
found that immunization markedly elevated also the tran-
scription of MT-I gene (Fig. 3A) and augmented the con-
tent of MT I + II proteins in lysates of spinal cord
(Fig. 3B, C). (p< 0.001 in comparison with intact and
CFA-treated rats). As shown in Fig. 3 D, MTs were upreg-
ulated diﬀusely in parenchyma of SC (a–f), in subependy-mal zones around the central canal
(a, b, e), on several astrocytes (d,
insert), as well as on blood vessels
endothelial cells (f, head arrows). Fur-
thermore, a very high MT immunore-
activity was found in neurons (c, f),
suggesting that they were similar to
those expressing OPN (Fig. 2D f). In
contrast, the expression of MT-I + II
in spinal cord of CFA-treated rats
was absent or very low (Fig. 3D g,
h). Beside, in negative controls the
immunopositivity was not observed
(Fig. 3D inserts on g, h).Relationship of OPN to CD3,
GFAP, CD44 and aVb3 in the spinal
cord
By double immunoﬂuorescent
analyses we next tried to determine
the type of cells that express OPN
and the relationship of OPN to its
receptors CD44 and aVb3 integrin.
The data have shown (Fig. 4 A) thatwithin the spinal cord of EAE rats were present several
CD3+ lymphocytes (a) and GFAP+ astrocytes (d).
They, however, did not co-express OPN (c, f), implying
that during the ﬁrst attack of EAE, OPN was more
expressed on other types of mononuclear cells. In the
aﬀected tissue were also present cells expressing CD44
(g), but they also did not co-express OPN (i). In
contrast, a high OPN-immunoreactivity was found in
almost all neurons expressing aVb3 integrin (l, arrows).
Moreover, as emphasized on Fig. 4B (a–c, arrows),
many of them contained OPN-positive granular deposits
in perinuclear location, suggesting that, in these neurons
OPN was directed to secretory pathway. Double
staining for OPN and GM 130, a marker of Golgy,
conﬁrmed this hypothesis (Fig. 4B e–g, arrows), and
labeling of OPN and NeuN conﬁrmed that the
accumulation of OPN-positive granular deposits
occurred in mature neurons (Fig. 4B h–j). Noteworthy,
similar ﬁndings were not found in CFA-treated rats
(Fig. 4B d), showing that upregulation of OPN in aVb3+
neurons was speciﬁc for the encephalitogen-induced
processes. On slides used as negative controls
ﬂuorescent signals were not detected at all (not shown).Co-expression of OPN and MT-I + II in the spinal cord
Immunoﬂuorescent analyses conﬁrmed that during the
attack of EAE in spinal cord arose the expression of
MT-I + II (Fig. 5A) on blood vessels endothelial cells (a,
arrow), on agglomerates of mononuclear cells (d), as
well as on neurons (g) and some stromal aVb3+ cells
(j). OPN-positive cells around the vessels (b) did not
express MT (c, arrow), but MT+ cells in agglomerates
(d) expressed also a high OPN immunoreactivity (f).
Moreover, the co-staining of MTs and OPN was found
in soma of numerous neurons (i). In these MT+
neurons, OPN was visible in granular deposits
Fig. 2. OPN transcription, proteolytic cleavage and protein expression are increased in spinal cord
(SC) during the ﬁrst relapse of EAE. Samples of lumbar SC were obtained from untreated rats,
from rats treated by CFA and from rats exhibiting hind led paralysis after treatment with brain
homogenate (BBH) in complete Freund’s adjuvant (CFA)(post-immunization day 13 or 14). (A)
Relative expression levels of OPN mRNA (normalized to b-actin), determined by real-time PCR
(N= 4). (B) Representative, original Western blots of cytoplasmic fraction of SC, showing diﬀerent
OPN forms (full length OPN – 66 kDa and cleaved forms of OPN – 40 kDa and 32 kDa), b-actin
(used as a loading control) and b-tubulin (used as cytoplasmic marker) (N= 3). (C) Expression of
OPN protein in cytoplasmic fraction shown as OPN/b-actin ratio. Values refer to means ± SEM.
(D) Immunohistochemical staining of OPN protein in paraﬃn-embedded sections of the lumbar SC
tissue in DA rats treated by BBH+ CFA (a–f) or CFA (g, h). Arrows on (a–c) point to areas of
plaque, blood vessels and choroid plexus, respectively. Red arrow heads on (e) point to
upregulation of OPN on lymphoid cells around the blood vessels. Inserts on (g) and (h) show tissue
staining in section incubated without primary anti-OPN antibodies (negative control). The results
are representative ﬁndings of three rats. *p< 0.05 (One-way ANOVA followed by the post hoc
Scheﬀe´ test or Kruskal–Wallis test). Scale bars 100 lm (a, b), 20 lm (c, g) and 10 lm (d–f, h). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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and nuclear immunostaining (Fig. 5A i and B a, c, head
arrows), suggesting that OPN might be located also
outside of the secretory vesicles. Similar changes were
not observed in CFA-treated rats (Fig. 5B d).Expression and tissue distribution of OPN in the
brain
The data obtained by immunohistochemistry clearly
showed that during ﬁrst relapse of EAE the OPN
expression was markedly upregulated (Fig 6a–l) in
comparison with ﬁndings in CFA-treated rats (Fig. 6m–
p) in following locations: choroid plexus (a), in
subependymal area (b, c), in group of large cells insubventricular zone (d), in cortex (e),
in oligodendrocyte-like cells in white
matter (f), in hippocampus (CA1,
gyrus dentatus and subgranular
zone; g–i, respectively), as well as in
cerebellum (Purkinje cells and
medullar neurons; j–l).Relationship of OPN to cells
expressing aVb3 in the brain
Owing to the ﬁndings in SC (Fig. 4), in
the brain of rats treated by BBH
+ CFA we estimated particularly the
relationship of OPN to neurons
expressing aVb3. The data (Fig. 7)
clearly showed that OPN-
immunoreactivity was present in
cortical aVb3+ neurons (a–c) and in
several large cells located in
subventricular zone (d–f). Co-
staining of OPN and aVb3 was
found also on Purkinje cells in
cerebellum (j–l). aVb3 was highly
upregulated also in granular cell
layer (GCL) of hippocampus, but
only some of these neurons
expressed OPN immunoreactivity
(g–i). However, as emphasized in
Fig. 7B, almost all aVb3+ cortical
cells (a–c, arrows) and NeuN
+ neurons (h–j) exhibited high
granular OPN immunoreactivities in
structures stained with GM 130
antibodies (e-g, arrows), conﬁrming
that in these neurons OPN was
conﬁned to the secretory pathways.
In control, CFA-treated rats,
moderate expression of integrin
aVb3 was noticed in the
hippocampus (not shown), but in
contrast to ﬁndings in BBH+ CFA
treated rats, cortical neurons of
control rats did not co-express OPN
(Fig. 7 B d versus F A c).Relationship of OPN to MT-I + II in
the brainSingle and double labeling of brain sections for OPN and
MT in EAE rats showed that OPN and MT-I + II were co-
expressed in numerous cortical neurons (Fig. 8A a–c; B
a), in Purkinje cells in cerebellum (A j–l) and some cells
located n GCL of hippocampus (A g–i, arrows). In
corresponding brain areas of rats treated only with CFA
the similar changes were not found (Fig. 8A, inserts on
c, f, i, l). A high, encephalitogen-induced, co-staining of
MTs and OPN was found also in the choroid plexus
(Fig. 8B c versus d), as well as on large cells in
subventricular zone (SVZ) (Fig. 8A d–f; B b, arrows),
which has been considered responsible for the
expansion and proliferation of the stem/progenitors
Fig. 3. Metallothionein (MTs) transcription and protein expression are increased in spinal cord
(SC) during the ﬁrst relapse of EAE. Samples of lumbar SC were obtained from untreated rats,
from rats treated by CFA and from rats exhibiting hind led paralysis after treatment with brain
homogenate (BBH) in complete Freund’s adjuvant (CFA) (post-immunization day 13 or 14). (A)
Relative expression levels of MT-I mRNA (normalized to b-actin), determined by real-time PCR
(N= 4). Values refer to mean ± SEM. (B) Representative original Western blots of cytoplasmic
fraction of SC showing MT-I + II, b-actin (used as a loading control) and b-tubulin (used as
cytoplasmic marker) (N= 3). (C) Expression of MT I + II proteins in cytoplasmic fraction shown
as MTs/b-actin ratio. (D) Immunohistochemical staining of MT I + II protein in paraﬃn-embedded
sections of the lumbar SC tissue in DA rats treated by BBH+ CFA (a–f) or CFA (g–h). Arrows on
(a, b, e) point to central canal. Insert on (d) show astrocyte. Head arrows on (f) point to blood
vessel. Inserts on (g) and (h) show tissue staining in section incubated with isotypic IgG (negative
control). The results are representative ﬁndings of three rats. *p< 0.05 (One way ANOVA followed
by the post hoc Scheﬀe´ test or Kruskal–Wallis test). Scale bars 100 lm (a, g), 20 lm (b, c) or
10 lm (d–f, h).
H. Jakovac et al. / Neuroscience 350 (2017) 133–145 139during brain repair (Alvarez-Buylla et al., 2001; Alagappan
et al., 2009). Our data, showing the presence of PCNA in
these cells (Fig. 8A e, inserted picture) seem to support
this possibility and imply that OPN and MT-I + II might
inﬂuence their proliferation. Interestingly, in these MT+/
PCNA+ cells OPN immunoreactivity was not found in
perinuclear granules, but in patches adjacent to the
plasma membrane (Fig. 8A f, B b), suggesting that in
these mitotically active neuronal progenitors OPN was
present outside of the secretory pathway.
DISCUSSION
Profound inﬂuences of OPN and ECM on basic cellular
processes that aﬀect the pathogenesis of MS and EAE
have been repeatedly suggested (Steinman, 2009; Niino
and Kikuchi, 2011; Brown, 2012; Plantman, 2013;Kahles et al., 2014; Rittling and
Singh, 2015; Subraman et al., 2015).
However, although it is known that
OPN is one of the genes most highly
expressed in autoimmune demyeli-
nating lesions (Chabas et al., 2001),
as well as that it contributes to the
development of cell-mediated inﬂam-
matory responses (O’Regan et al.,
2000; Cantor and Shinohara, 2009;
Inoue and Shinohara, 2011; Rittling
and Singh, 2015), the complex inter-
play between supportive and inhibi-
tory molecules in these events is not
yet fully understood, similarly as the
mechanisms that lead to the genera-
tion of functionally distinct forms of
OPN during an autoimmune attack.
The data presented in this report
are generally in line with the updated
knowledge about the expression of
OPN in EAE (Niino and Kikuchi,
2011), but the results point also to
the relatively unknown interactions of
OPN with MT I + II, implying that in
some cells the pro-inﬂammatory prop-
erties of OPN can be balanced by the
activation of cytoprotective, MT-
related pathways, or that MT may
enhance the pro-regenerative and
anti-apoptotic properties of OPN.
Hypothesis is based on our ﬁndings
that during peak stage of EAE mRNA
and protein expression of OPN arose
concurrently with the transcription of
MT-I and expression of MT-I + II pro-
teins (Figs. 2 and 3) and that several
inﬂammatory cells, glial cells and neu-
rons in the spinal cord and in the brain
express both OPN and MT I + II
immunoreactivities (Figs. 4–5, 7–8).
The data also suggest that these
interactions might be linked with the
proteolytic cleavage and posttransla-
tional modiﬁcation of OPN, since we
found that cytoplasmic fraction of SClysates from EAE rats contained greater amount of OPN
with low molecular weight (32 kDa) than corresponding
fractions obtained from CFA-treated and intact rats
(Fig. 2B, C). This hypothesis seems to be supported by
ﬁndings that OPN fragments of 40, 32, and 25 kDa may
be generated by cleavage of OPN with MMP-3
(stromelysin-1) and MMP-7 (matrilysin) (Agnihotri et al.,
2001; Gao et al., 2004) and by data showing that the N-
and C-terminal fragments of OPN (with approx 35 kDa
and 25 kDa, respectively) may be produced by cleavage
of OPN by thrombin (Morimoto et al., 2010; Boggio
et al., 2016). In our study the proteolytic cleavage of
OPN should be better deﬁned by the use of mAb speciﬁc
for OPN sequences and by determination of functional
activity of the generated segments, but it is noteworthy
Fig. 4. Relationship of OPN to T lymphocytes, astrocytes and cells expressing CD44 and aVb3
integrin. (A) T lymphocytes (a), astrocytes (d) CD44 (g) and aVb3 (j) expressing cells were
detected by anti-CD3, anti-GFAP, anti-CD44 and anti-aVb3, respectively (red staining) in paraﬃn
sections of SC tissue removed on the 13th–14th post-immunization day from paralyzed EAE rats
(a–l). Green marks OPN staining by anti-OPN antibodies, blue marks DAPI staining of nuclei and
yellow marks the overlapping of OPN with other markers. (B) Representative images (N= 3) show
granular OPN deposits in aVb3+ (a–c, arrows) and NeuN+ (h–j) neurons of EAE rats, as well as
their accumulation in secretory vesicles of Golgy, labeled by anti-GM 130 monoclonal antibodies
(e–g, arrows). Scale bars: 20 lm (A a–l, B d); 10 lm (B, a–c, e–j). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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new properties and expose higher adhesive activities for
integrins, owing to the exposure of RGD motif and a cryp-
tic SVVYGLR or SLAYGLR segments on N-terminal frag-
ment of OPN molecule (Agnihotri et al., 2001; Gao et al.,
2004; Boggio et al., 2016). In this context Boggio and co-
workers (2016) recently clearly showed the recombinant
proteins corresponding to the full length OPN and
thrombin-cleaved OPN forms (OPN-N and OPN-C),
exerted diﬀerent eﬀects on adhesive, migratory and
secretory activity of T cells and monocytes and other cru-
cial processes that contribute to the homing of autoreac-
tive lymphocytes and formation of demyelinating lesions
in the CNS. Moreover, underlining that thrombin-
mediated cleavage of OPN plays a key role also in vivo
these authors showed that administration of OPN-FL,
OPN-C and OPN-C + OPN-N in the remission phase of
disease induced a prompt relapse of EAE in mice immu-nized with MOG35–55, as well as that
OPN-FL was much more eﬀective in
inducing EAE relapses than OPN-
FLmut, which was resistant to
thrombin-mediated cleavage (Boggio
et al., 2016). Similarly, Goncalves
DaSilva and co-workers (2010)
demonstrated that OPN mRNA and
protein expression in the spinal cord
of EAE-aﬄicted mice arose concur-
rently with MMP-12 expression, as
well as that OPN-immunoreactive
bands in the spinal cord of EAE mice
had a pattern similar to MMP-12
cleavage of recombinant OPN
in vitro. Interestingly, their data also
showed that cleavage of OPN by
MMP-12 might be beneﬁcial for EAE
mice, since in MMP-12_/_ mice the
exacerbated EAE was found
(Goncalves DaSilva et al., 2010).
Furthermore, for our data it may
be relevant that Morisaki et al.
(2016) in rodent models of amy-
otrophic lateral sclerosis (ALS), found
that OPN in spinal motor neurons
stimulated MMP-9 transcription and
expression through avb3 integrin-
mediated transduction. In this condi-
tion the activation of OPN-integrin
avb3-MMP-9 axis has been viewed
as a sign of selective motor neurons
vulnerability and second-wave neu-
rodegeneration in ALS, but the contri-
bution of these processes to active
remodeling of neurons was also
emphasized (Morisaki et al., 2016).
Our data, showing that in SC of
EAE-rats are generated OPN
fragments of small size (Fig. 1B, C),
as well as that in numerous aVb3+
neurons (Figs. 5 and 8) are present
both OPN and MT proteins (Figs. 5
and 8), imply that in coordinatedmolecular response activated after intraneuronal
distress participate not only OPN and MMP, but also the
metal binding proteins – MT-I + II. The underlining
mechanisms of this cross talk are unclear, but taken
into account the evidence pointing to detrimental
functions of OPN in EAE (Chabas et al., 2001; Jansson
et al., 2002; Kim et al., 2004; Brown, 2012) and those
showing that MT-I + II have marked cytoprotective, anti-
inﬂammatory and neuroprotective properties (Hidalgo
et al., 1991; Mocchegiani et al., 2000; Penkowa et al.,
2003; Penkowa and Hidalgo, 2003; Penkowa, 2006;
Pedersen et al., 2009; Manso et al., 2011) we may spec-
ulate that molecular changes induced by MTs in cellular
compartment might restrain the pro-inﬂammatory eﬀects
of OPN or increase the anti-inﬂammatory properties of
OPN and viability of target cells. Eﬀects might be related
with the ability of MT to serve as a storage protein from
Fig. 5. Expression of MT-I + II and OPN in spinal cord during ﬁrst relapse of EAE. (A) Cells
expressing MTs, OPN and aVb3 were detected with anti-MT-I + II (a, d, g – red staining; j – green
staining), with anti-OPN (b, e, h – green staining), and with anti-aVb3 antibodies (k – red staining)
respectively, in paraﬃn sections of tissue obtained from rats treated with BBH+ CFA (a–l). Blue
marks DAPI staining of nuclei and yellow marks the overlapping of OPN with other markers. (B)
Representative images (N= 3) show granular OPN deposits (b, arrow), cytoplasmic and nuclear
OPN immunoreactivities (a, c, arrow heads) in EAE rats and ﬁndings in CFA-treated rats (d). Scale
bars: 20 lm (A a–l, B d); 10 lm (B a–c). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 6. Expression of OPN in brain regions during ﬁrst relapse of EAE. Brain tissue was obtained
from rats treated with BBH+ CFA (a–l) or from CFA-treated rats (m–p). Paraﬃn sections were
immunostained for OPN and counterstained with hematoxylin. Inserts on (m–p) show tissue
staining in section incubated without primary anti-OPN antibodies (negative control). The results
are representative ﬁndings of three rats. Scale bars: 20 lm or 10 lm (third column and inserts on
m–o).
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cysteine oxidation, as well as with its
ability to act as antagonist of toxic
metals and organic molecules, as
scavenger of reactive oxygen and
nitrogen species and as a regulator
of zinc-ﬁnger and p53 and other
metal-containing transcription factors
(Andrews, 2000; Davis and Cousins,
2000; Mocchegiani et al., 2000;
Lynes et al., 2006; Rink and Haase,
2007; Inoue et al., 2009; Isani and
Carpene, 2014; Ling et al., 2016).
Moreover, for our data showing
OPN/MT co-expression in neurons
(Figs. 5 and 8) it may be particularly
relevant that MTs may prevent
demyelination and axonal damage
and increase oligodendrocyte precur-
sors proliferation during EAE
(Penkowa and Hidalgo, 2003) and
preserve the mitochondrial structural
and functional integrity by augmenta-
tion of mitochondrial coenzyme Q10,
glutathione, ferritin, melatonin, and
neuromelanin synthesis in neurons
(Sharma et al., 2013).
As shown by Ambjrˇrn and
coworkers (2008), the survival-
promoting eﬀects of MT and its syn-
thetic analog EmtinB on neurons
include binding of MT to surface
receptors of the low-density lipopro-
tein receptor (LDLR) family, such as
megalin and lipoprotein receptor-
related protein-1, and activation of
signal transduction pathways that
promote neurite outgrowth and sur-
vival or abrogate the apoptosis. In this
context we may speculate that bind-
ing of MT to multiligand, surface
receptors might aﬀect also the OPN-
avb3 integrin-MMP-9 axis and other
post-translational processes, such as
phosphorylation, glycosylation and
sulfation that determine OPN signal-
ing and its functions in various cell
types (Kazanecki et al., 2007;
Kahles et al., 2014)..This speculation,
however, remains to be proved, simi-
larly as the possibility that MT/zinc
network aﬀects the cell-autonomous
immune mechanisms in neurons that
trigger a pathogenic cascade after
binding of endogenous molecules
produced by stress (heat shock pro-
teins, mRNA, ﬁbrinogen, mitochon-
drial DNA) to TLRs in injured cells
(Czirr and Wyss-Coray, 2012). Note-
worthy, TLR3, -7, -8, and -9 are
located in the ER and endosomal
Fig. 7. Relationship of OPN to cells expressing aVb3 in the brain during ﬁrst relapse of EAE. (A)
Cells expressing aVb3 integrin and OPN were detected with anti-aVb3 (red staining) and anti-OPN
(green staining) antibodies, respectively, in paraﬃn sections of tissue obtained from rats treated
with BBH+ CFA (a–l). Blue marks DAPI staining of nuclei and yellow marks the overlapping of
OPN with aVb3. (B) Representative images (N= 3) show granular OPN deposits in cortical aVb3
+ (a–c) and NeuN+ (h–j) neurons, as well as their accumulation in secretory vesicles of Golgy,
labeled by anti-GM 130 monoclonal antibodies (e–g) in EAE rats and ﬁndings in CFA-treated rats
(d). Scale bars: 20 lm (A a–l, B d); 10 lm (B a–c, e–j). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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deposits (Figs. 4, 7), and their activation can lead to initi-
ation of autophagy and induce the clearance of defective
organelles or protein aggregates (Czirr and Wyss-Coray,
2012). Moreover, it should be taken into account that the
cytosolic Zn level is regulated also by Zn transporters of
the Slc39/ZIP and Slc30/ZnT families and that Zn may
function as an intracellular signaling molecule or second
messenger, either independently, or in a manner depen-
dent on the transcriptional changes of Zn transporters or
MTs (Fukada et al., 2011).
Altogether, these evidence imply that the outcome of
OPN/MT interaction in neurons might be the abrogation
of detrimental functions of OPN or the stimulation of
pro-regenerative and anti-apoptotic properties of OPN
(Carecchio and Comi, 2011; Plantman, 2013) The latter,
is emphasized also by ﬁndings that recombinant OPN
upregulates myelination and remyelination in in vitro cellu-
lar cultures (Selvaraju et al., 2004), by data showing that
RGD-containing peptide fragment of OPN protects
dopaminergic neurons against toxic insult (Iczkiewiczet al., 2010), as well as by ﬁndings
that OPN stimulates neurite growth
of hippocampal neurons (Plantman,
2012) and facilitates the regeneration
of motor neuron axons (Wright et al.,
2014).
Herein we also show that during
ﬁrst attack of EAE the expression of
OPN and MT-I + II increases at
sites of cellular invasion and T cell
reactivation, such as BBB, choroid
plexus and leptomeninges around
the spinal cord (Figs. 3, 4), as well
as that several ependymal cells and
inﬂammatory cells around the blood
vessels in demyelinating plaques co-
localize OPN and MT (Fig. 8). These
data are in high agreement with
evidence showing that both OPN
(Shinohara et al., 2008a; Cantor and
Shinohara, 2009; Morimoto et al.,
2010; Inoue and Shinohara, 2011;
Hellewell and Adams, 2015) and MT/
Zn network have high impact on
innate and adaptive immunity
(Mocchegiani et al., 2000; Prasad,
2008; Fukada et al., 2011; Haase
and Rink, 2014). The mechanisms of
OPN/MT interaction in our experi-
mental model, however, remain to
be elucidated, since in the develop-
ment of EAE are involved various cell
types and diﬀerent OPN isoforms
(Cantor and Shinohara, 2009). Thus,
the plasmacytoid DC, containing i-
OPN, may be more responsible for
the generation of pro-inﬂammatory
TH17 cells and the onset of EAE
(Shinohara et al., 2008a). In contrast,
it is likely that s-OPN, produced by
activated T-cells, contributes more tothe development of relapse and progression of EAE
(Hur et al., 2007). However, as shown by Boggio et al.
(2016) the OPN activity in all these steps may be depen-
dent on thrombin-induced cleavage, since OPN eﬀects on
IL-17 and IL-6 secretion and cell migration were mainly
ascribable to OPN-N, whereas those on IL-10 secretion
and cell adhesion were mainly mediated by OPN-C.
Our data imply that during ﬁrst attack of EAE OPN and
MTs were more expressed in monocyte and microglia-like
cells (Fig. 5A f) and that OPN activities were more related
to its RGD-binding domain of OPN than to OPN-C
fragment, but in spite of the fact that these ﬁndings are
in line with current knowledge showing that binding of
RGD fragment of many ECM proteins leads to activation
and conformational change of integrin receptor and
activation of an ‘‘outside-in” and an ‘‘inside-out”
signaling cascades (Wu and Reddy, 2012) our study
requires additional phenotypic and functional analyses.
In conclusion our data show that acute phase of EAE
in DA rats is followed by increased transcription of OPN
Fig. 8. Expression of MT-I + II and OPN in the brain during ﬁrst relapse of EAE. (A) Cells
expressing MTs and OPN were detected by the use of anti MT-I + II (red staining) and anti-OPN
antibodies (green staining), respectively in paraﬃn sections of tissue obtained from rats treated
with BBH+ CFA (A a–l) and rats treated only with CFA (inserts on A c, f, i, l). Embedded picture
on (e) shows the presence of proliferating cellular nuclear antigen (PCNA) (red staining). Blue
marks DAPI staining of nuclei and yellow marks the overlapping of OPN with MT-I + II or PCNA.
B) Representative images (N= 3) show OPN immunoreactivity in cortical neurons (a), in
subventricular zone (b) and in choroid plexus (c) of EAE rats and ﬁndings in choroid plexus of CFA-
treated rats (d). Scale bars: 20 lm (A a–l, B d); 10 lm (B a–c). (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
H. Jakovac et al. / Neuroscience 350 (2017) 133–145 143and MT-I gene, by signs of proteolytic cleavage of OPN
and increased synthesis of MT-I + II proteins in SC, by
enhanced expression of OPN and MT proteins in the
spinal cord and in the brain, as well as by co-expression
of OPN and MTs in numerous cells, implying that during
autoimmune attack the harmful properties of OPN might
be, particularly in avb3+ neurons, restrained by
cytoprotective activities of MTs.AUTHORS’ CONTRIBUTION
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